A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors-Reference-Cited by-同舟云学术

A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors

Published:2022-08 Issue:7 Volume:51 Page:763-768
ISSN:1536-4828
Container-title:Pancreas
language:en
Short-container-title:Pancreas

Author:

Perez Kimberly,Kulke Matthew H.,Horick Nora K.,Regan Eileen,Graham Christopher,Scheutz Samantha,Stonely Danielle,Enzinger Peter C.,Fuchs Charles S.,Allen Jill N.,Enzinger Andrea C.,Clark Jeffrey W.,Chan Jennifer A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors;Cancer,2007

2. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202);J Clin Oncol,2019

3. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509);J Clin Oncol,2021

4. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET);J Clin Oncol,2017

5. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study;Lancet Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-23

2. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09